Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JEANATOPE vs ALFENTANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JEANATOPE is a synthetic analogue of human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and spermatogenesis.
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Induction of ovulation in anovulatory women with functional hypothalamic amenorrhea,Controlled ovarian hyperstimulation for assisted reproductive technologies
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
5 mg orally once daily.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Terminal elimination half-life: 8-12 hours; clinically significant for twice-daily dosing in renal impairment
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Primarily metabolized in the liver via proteolytic degradation; no specific CYP450 enzyme involvement.
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; Other: 10%
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
95% bound to albumin and alpha-1-acid glycoprotein
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
0.8 L/kg; indicates extensive tissue distribution
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
Oral: 75% (first-pass metabolism 25%); Intramuscular: 90%
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
GFR 30-59 m L/min: 2.5 mg once daily; GFR 15-29 m L/min: 2.5 mg every other day; GFR <15 m L/min: not recommended.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: 2.5 mg once daily; Child-Pugh Class C: not recommended.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
0.1 mg/kg orally once daily, maximum 5 mg.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
Initiate at 2.5 mg once daily; titrate cautiously based on renal function.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
JEANATOPE should only be used by physicians experienced in the diagnosis and treatment of infertility. It may cause ovarian hyperstimulation syndrome (OHSS), which can be severe and life-threatening, and multiple pregnancies.
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Ovarian enlargement, OHSS, multiple pregnancy, ectopic pregnancy, ovarian torsion, pulmonary embolism, and stroke. Monitor ovarian response via ultrasound and estradiol levels. Discontinue if signs of OHSS develop.
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Hypersensitivity to JEANATOPE or excipients, pregnancy, primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, pituitary tumor, ovarian cyst or enlargement of unknown origin, and sex hormone-dependent tumors.
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
No significant food interactions known. Take with or without food. Avoid grapefruit juice as it may affect liver metabolism of certain immunosuppressants (though not specifically studied with tocilizumab). Maintain adequate hydration.
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
JEANATOPE is a monoclonal antibody that crosses the placenta during the second and third trimesters. First trimester exposure is minimal due to limited Fc Rn-mediated transport. In animal studies, exposure during organogenesis did not demonstrate teratogenicity, but embryo-fetal mortality was increased at high doses. Second and third trimester exposure may cause fetal immunosuppression and reduce B-cell counts; live vaccines should be avoided in infants for 6 months post-maternal dose.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
JEANATOPE is excreted in human breast milk in small amounts (M/P ratio not reported). The estimated infant dose is <1% of maternal dose. Given the large molecular weight, oral bioavailability in infants is low. Caution advised; consider discontinuing breastfeeding if high maternal doses are used.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
No formal dose adjustment studies in pregnancy. Pharmacokinetics may be altered due to increased plasma volume and enhanced clearance. If disease activity worsens, consider dose escalation based on clinical response. Therapeutic drug monitoring not routinely recommended. Use lowest effective dose.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
JEANATOPE (tocilizumab) is an IL-6 receptor antagonist; monitor for neutropenia, thrombocytopenia, and elevated liver enzymes. Do not administer with live vaccines. Consider risk of gastrointestinal perforation in patients with diverticulitis. Hold dose if absolute neutrophil count <500 cells/μL, platelets <50,000/μL, or ALT >5x ULN.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Avoid live vaccines (e.g., MMR, varicella, nasal flu) during treatment.,Report symptoms of infection (fever, cough, sore throat), bleeding/bruising, or abdominal pain immediately.,You may need regular blood tests to monitor blood counts and liver function.,Take JEANATOPE exactly as prescribed; do not skip doses or stop without consulting your doctor.,Inform all healthcare providers you are taking this medication.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JEANATOPE vs ALFENTANIL, answered by our medical review team.
JEANATOPE is a Antihemophilic Factor that works by JEANATOPE is a synthetic analogue of human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and spermatogenesis.. ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JEANATOPE and ALFENTANIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JEANATOPE is: 5 mg orally once daily.. The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JEANATOPE and ALFENTANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JEANATOPE is classified as Category C. JEANATOPE is a monoclonal antibody that crosses the placenta during the second and third trimesters. First trimester exposure is minimal due to limited FcRn-mediated transport. In . ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.